Interlesional response assessment with 18F-sodium fluoride (18F-NaF) PET/CT in men with chemotherapy-naive bone metastatic castration-resistant prostate cancer (mCRPC) treated with enzalutamide (ENZA).

Christos Kyriakopoulos,Elisabeth I. Heath,Anna C. Ferrari,Scott B. Perlman,Tina M. Mayer,Mark N. Stein,Katharina Modelska,William T. Duggan,Robert Jeraj,Glenn Liu

Interlesional response assessment with 18F-sodium fluoride (18F-NaF) PET/CT in men with chemotherapy-naive bone metastatic castration-resistant prostate cancer (mCRPC) treated with enzalutamide (ENZA).

2019

Christos Kyriakopoulos
Elisabeth I. Heath
Anna C. Ferrari
Scott B. Perlman
Tina M. Mayer
Mark N. Stein
Katharina Modelska
William T. Duggan
Robert Jeraj
Glenn Liu

5036Background: 18F-NaF PET/CT provides spatial and quantitative information on osteoblastic activity in men with bone mCRPC; thus, it can be used to assess interlesional response heterogeneity, a ...

Keywords:

Prostate cancer
Castration
Internal medicine
PET-CT
Oncology
Pathology
Sodium fluoride
Medicine
Enzalutamide
Chemotherapy
response assessment
response heterogeneity
castration resistant
chemotherapy naive

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations